Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. (Q36735202)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

methicillin-resistant Staphylococcus aureus

25 December 2019

main subject

0 references

1 reference

1 reference

ChEBI release 2020-05-28

ChEBI ID

28001

Staphylococcus aureus

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Darego O Maclayton

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

language of work or name

English

0 references

publication date

13 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

Annals of Pharmacotherapy

25 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

235-244

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

Prevention of hospital-associated pneumonia and ventilator-associated pneumonia

25 December 2019

cites work

1 reference

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

21 January 2018

1 reference

Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database

21 January 2018

1 reference

Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.

21 January 2018

1 reference

Methicillin-resistant-Staphylococcus aureus hospitalizations, United States

21 January 2018

1 reference

Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes

21 January 2018

1 reference

Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy

21 January 2018

1 reference

Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia

21 January 2018

1 reference

Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia

21 January 2018

1 reference

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

21 January 2018

1 reference

Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia.

21 January 2018

1 reference

Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?

21 January 2018

1 reference

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

21 January 2018

1 reference

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

21 January 2018

1 reference

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

21 January 2018

1 reference

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

21 January 2018

1 reference

Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs

21 January 2018

1 reference

Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices

21 January 2018

1 reference

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

Penetration of vancomycin into human lung tissue

21 January 2018

1 reference

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

21 January 2018

1 reference

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning

21 January 2018

1 reference

Outcome assessment of minimizing vancomycin monitoring and dosing adjustments

21 January 2018

1 reference

A prospective study of adverse reactions associated with vancomycin therapy

21 January 2018

1 reference

Intrapulmonary pharmacokinetics of linezolid

21 January 2018

1 reference

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses

21 January 2018

1 reference

Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics

21 January 2018

1 reference

Antimicrobial dosing in obese patients

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis

21 January 2018

1 reference

Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.

21 January 2018

1 reference

Serotonin toxicity associated with the use of linezolid: a review of postmarketing data

21 January 2018

1 reference

Linezolid and serotonergic drug interactions: a retrospective survey

21 January 2018

1 reference

Hematologic effects of linezolid: summary of clinical experience

21 January 2018

1 reference

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

21 January 2018

1 reference

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

21 January 2018

1 reference

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

21 January 2018

1 reference

Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.

21 January 2018

1 reference

Linezolid induced toxic optic neuropathy

21 January 2018

1 reference

Linezolid-associated toxic optic neuropathy: a report of 2 cases

21 January 2018

1 reference

Linezolid-induced inhibition of mitochondrial protein synthesis.

21 January 2018

1 reference

Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus

21 January 2018

1 reference

Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin

21 January 2018

1 reference

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

21 January 2018

1 reference

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Quinupristin-dalfopristin and linezolid: evidence and opinion

21 January 2018

1 reference

Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections

21 January 2018

1 reference

Safety and tolerability of quinupristin/dalfopristin: administration guidelines

21 January 2018

1 reference

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

21 January 2018

1 reference

Tigecycline: clinical evidence and formulary positioning

21 January 2018

1 reference

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

21 January 2018

1 reference

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

21 January 2018

1 reference

Novel antibacterial agents for the treatment of serious Gram-positive infections

21 January 2018

1 reference

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

21 January 2018

1 reference

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

21 January 2018

1 reference

The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?

21 January 2018

1 reference

MRSA pneumonia: better outcome through continuous infusion of vancomycin?

21 January 2018

1 reference

Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections

21 January 2018

1 reference

Antimicrobial resistance to linezolid

21 January 2018

1 reference

Epidemiological Profile of Linezolid‐Resistant Coagulase‐Negative Staphylococci

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17299012%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference